Suppr超能文献

接受枸橼酸他莫昔芬治疗患者的临床及活体共聚焦显微镜检查结果

Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate.

作者信息

Muftuoglu Orkun, Uçakhan Omür Ozlenen, Kanpolat Ayfer

机构信息

Department of Ophthalmology, School of Medicine, Ankara University, Ankara, Turkey.

出版信息

Eye Contact Lens. 2006 Sep;32(5):228-32. doi: 10.1097/01.icl.0000201396.74294.85.

Abstract

PURPOSE

: To describe the deposition rate of tamoxifen in the cornea and observe its impact on the cornea with confocal microscopy.

METHODS

: Forty-four eyes of 22 women receiving tamoxifen at a dosage of 20 mg/day for at least 6 months for the adjuvant treatment of breast cancer and 30 eyes of 15 healthy age-matched women were examined for corneal drug deposition by slitlamp after pupil dilation. Ultrasound pachymetry, specular microscopy, in vivo confocal microscopy, and Schirmer tear test were also performed in all patients.

RESULTS

: The mean duration of tamoxifen intake was 21.6 +/- 7.9 months (range, 13-44 months), and the mean cumulative dose was 12.9 +/- 4.7 g (range, 7.8-26.4 g). Drug depositions in the inferior paracentral cornea were identified in 32 (72%) eyes at pupil-dilated slitlamp examination. There were no significant differences between eyes with keratopathy, those without keratopathy, and control eyes in regard to the mean Schirmer test scores, mean central corneal thickness, mean endothelial cell count, mean basal epithelium cell density, mean anterior and posterior stromal keratocyte density, and mean endothelial cell density (P > 0.05). No pathologic alteration of structure was observed with in vivo confocal microscopy at any corneal level in patients receiving tamoxifen.

CONCLUSIONS

: Low-dose tamoxifen use was associated with corneal depositions in 72% of patients. Slitlamp examination performed with pupil dilation was helpful in detection of subtle tamoxifen-related deposits. Amelioration of in vivo confocal microscopy systems may be helpful in accurate imaging of the paracentral and peripheral cornea.

摘要

目的

描述他莫昔芬在角膜中的沉积率,并通过共聚焦显微镜观察其对角膜的影响。

方法

对22名接受他莫昔芬辅助治疗乳腺癌、剂量为20mg/天且至少服用6个月的女性的44只眼,以及15名年龄匹配的健康女性的30只眼进行散瞳后裂隙灯检查角膜药物沉积情况。所有患者还进行了超声角膜测厚、镜面显微镜检查、活体共聚焦显微镜检查和泪液分泌试验。

结果

他莫昔芬的平均服用时间为21.6±7.9个月(范围13 - 44个月),平均累积剂量为12.9±4.7g(范围7.8 - 26.4g)。散瞳裂隙灯检查发现32只眼(72%)在角膜中央下方有药物沉积。在泪液分泌试验平均得分、中央角膜平均厚度、内皮细胞平均计数、基底上皮细胞平均密度、前后基质角膜细胞平均密度和内皮细胞平均密度方面,患角膜病的眼、未患角膜病的眼和对照眼之间无显著差异(P>0.05)。接受他莫昔芬治疗的患者在任何角膜层面的活体共聚焦显微镜检查均未观察到结构的病理改变。

结论

低剂量使用他莫昔芬的患者中72%出现角膜沉积。散瞳后进行的裂隙灯检查有助于发现与他莫昔芬相关的细微沉积物。改进活体共聚焦显微镜系统可能有助于对角膜中央旁和周边进行准确成像。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验